Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy

S Wakasugi1, A J Fischman, J W Babich

  • 1Department of Radiology, Massachusetts General Hospital, Boston 02114.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 1, 1993
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delivery of proteins to CNS as seen and measured by positron emission tomography.

Drug delivery and translational research·2015
Same author

Investigation of intrathecal transport of NPT002, a prospective therapeutic based on phage M13, in nonhuman primates.

Drug delivery and translational research·2015
Same author

Nitric oxide activates intradomain disulfide bond formation in the kinase loop of Akt1/PKBα after burn injury.

International journal of molecular medicine·2013
Same author

Isolation rearing significantly perturbs brain metabolism in the thalamus and hippocampus.

Neuroscience·2012
Same author

SILAM for quantitative proteomics of liver Akt1/PKBα after burn injury.

International journal of molecular medicine·2011
Same author

Decreased regional cerebral blood flow in medial prefrontal cortex during trauma-unrelated stressful imagery in Vietnam veterans with post-traumatic stress disorder.

Psychological medicine·2011

Adriamycin cardiomyopathy impairs heart energy metabolism, decreasing glucose and fatty acid utilization. Early detection of reduced myocardial glucose uptake using 18F-FDG may indicate heart failure.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Biochemistry

Background:

  • Adriamycin (doxorubicin) is a potent chemotherapy agent with known cardiotoxic effects.
  • Cardiomyopathy induced by adriamycin leads to progressive left ventricular dysfunction.
  • Understanding metabolic alterations is crucial for early diagnosis and management of adriamycin cardiotoxicity.

Purpose of the Study:

  • To investigate changes in myocardial substrate utilization in a rat model of adriamycin-induced cardiomyopathy.
  • To correlate metabolic alterations with left ventricular function and cardiac damage.
  • To evaluate the potential of specific radiotracers for early detection of cardiotoxicity.

Main Methods:

  • Rats were treated with adriamycin weekly for up to 10 weeks.

Related Experiment Videos

  • Positron Emission Tomography (PET) with Fluorine-18-F-deoxyglucose (18F-FDG) assessed glucose metabolism.
  • Single Photon Emission Computed Tomography (SPECT) with Iodine-125-beta-methyl-branched fatty acid (125I-BMIPP) evaluated fatty acid metabolism.
  • SPECT with Technetium-99m-hexakis (2-methoxyisobutyl-isonitrile) (99mTc-MIBI) measured myocardial blood flow.
  • Left ventricular ejection fraction (LVEF) was determined using gated blood pool imaging.

    • Main Results:

    • Left ventricular ejection fraction (LVEF) significantly decreased from 6 weeks onwards.
    • Myocardial uptake of 18F-FDG progressively decreased, preceding LVEF deterioration.
    • Myocardial uptake of 125I-BMIPP also decreased in advanced stages, correlating with 18F-FDG reduction but less profoundly.
    • Myocardial blood flow (99mTc-MIBI) remained unchanged, indicating preserved perfusion.
    • Blood glucose levels were similar between control and adriamycin-treated groups.

    Conclusions:

    • Adriamycin-induced cardiomyopathy is characterized by impaired myocardial glucose and fatty acid utilization, contributing to heart failure.
    • Reduced myocardial glucose metabolism, detected by 18F-FDG, appears to be a sensitive early marker for adriamycin cardiotoxicity.
    • Metabolic changes precede functional decline, offering a potential window for intervention.